Spinol advances a new standard in annular repair.OctaSeal™ is a best-in-class, intradiscal annular closure technology—minimally invasive, tissue-preserving, and supported by five-year clinical data—addressing a ~$3B market with only one existing competitor. Visit website. https://spinolmed.com/

Hygea, as the No.1 Chinese Co-ablation developer had developed a strong pipeline in minimally Invasive Oncology area including 85℃/-196℃ Co-Ablation(FDA/CE/CFDA), Irreversible Electroporation(IRE), Microwave Ablation (MWA, FDA/CE/CFDA) systems and TACE Biodegradable Microspheres, based on its percutaneous ablation and Endovascular intervention platforms. More than 30K+ patients globally benefit from company’s innovation since its 1st Co-ablation system launched in 2017.

ComplyWise is a real-time healthcare data validation platform that analyzes clinical and claims data against compliance rules to improve clinical workflows and proactively identify potential compliance and data quality issues.

Inova Medical Pty Ltd is an Australian medical technology company developing innovative solutions for sustainable healthcare. The company’s Abcease™ Kit is a sterile, single-use device designed to enable safe, efficient drainage of deep and superficial skin abscesses in ambulatory settings. Designed for ease of use and accessibility, the Abcease™ Kit aims to move skin abscess treatment away from in-patient, surgical treatment, and facilitates streamlined treatment in an ambulatory setting utilising local anaesthetic. Inova Medical aims to streamline procedures and optimise resource utilisation by creating the tools clinicians need.

THERYQ is an innovative medical technology company specializing in the design and production of FLASH radiotherapy machines—a breakthrough technology with the potential to improve cancer treatment by reducing side effects. It aims to enhance outcomes for cancers already treatable today (such as breast and prostate) and to offer new therapeutic options for cancers that currently have limited or no effective treatments (such as glioblastoma and pancreatic cancer).

METS_iQ is a clinical decision support platform that combines proprietary indirect calorimetry hardware (ECAL) with cloud-based metabolic analysis to measure and manage patient metabolism during obesity management and GLP-1 therapy. The system provides objective metabolic measurement, treatment stratification, and response monitoring within clinical care pathways.

Lubdub Technologies develops accessible cardiovascular diagnostic technologies for point-of-care and remote monitoring applications. Its platform combines wearable ECG, saliva-based cardiac biomarker testing, and wearable echocardiography technologies to support continuous heart health assessment and earlier clinical decision-making across healthcare settings.

Nu Eyne develops non-invasive neuromodulation medical devices for neurological and neuropsychiatric disorders.Its core technology delivers targeted electrical stimulation to modulate neural activity, with product pipelines focused on migraine, ADHD, ASD, and other nervous system-related conditions.

SiBionics is a commercial-stage medical device company offering the GS1 Continuous Glucose Monitoring (CGM) System, a calibration-free, 14-day wearable sensor for diabetes care. The technology uses an integrated electrochemical sensor to provide real-time glucose readings every five minutes directly to a smartphone. Differentiated by its high clinical accuracy (8.83% MARD), waterproof design, and user-friendly "all-in-one" form factor, SiBionics provides a seamless, data-driven alternative to traditional blood glucose monitoring for millions of users worldwide.

Biorithm is a medical technology company focused on advancing maternal and fetal care through digital health solutions. The company's flagship product, femom, is a remote monitoring platform that includes a clinical-grade fetal-maternal monitor, patient-reported symptom tracking, and connected point-of-care devices like blood pressure monitors and glucometers. The femom system enables clinicians to remotely assess the health of expectant mothers and their babies, facilitating early detection of complications and personalized care plans. Currently in the clinical investigation phase, femom aims to enhance continuity of care and empower patients and providers with data-driven insights.

Innovate Medtech is a medical device innovation studio that develops core technology for Class II and III devices. Capabilities include advanced materials (hydrogel membranes, flexible electronics, sensors, electrochemical biosensors and IVDs), prototyping, design control, IP strategy, and regulatory pathway planning. Beyond technology development, the company works closely with founders to help build both the product and the company around it, supporting the journey from early concept through to commercialisation and scale-up.

Earflo is a medtech company developing a non-invasive solution for childhood middle-ear disease. Designed to resemble a child’s sippy cup, the Earflo device uses a proprietary control algorithm to deliver a brief, carefully timed pulse of air during swallowing to help ventilate the middle ear. By treating the negative middle ear pressure associated with Otitis Media with Effusion (OME) at home, Earflo aims to provide families with an accessible alternative before progressing to invasive surgical intervention.

Neuroloop’s endeavor is to set new standards in treating chronic diseases by replacing drugs with electricity - where pharmacological treatments are limited or have failed. Thus, we will develop a platform based on thin-film technology for controllable selective stimulation of the vagus nerve. The first indication we are focusing on within our product pipeline is true resistant hypertension. We are currently testing our product in a clinical trial in several European countries.

Corcillum is developing a software-based digital twin of the heart arteries that uses AI and physics-based simulation to derive functional measures of pressure, microvascular function and plaque risk from standard Xray angiogram images.

Spirecut AG is a commercial-stage, ISO 13485-certified Swiss medical device company revolutionizing surgery with patented, incisionless surgical instruments. Spirecut’s solution is a game changer for the healthcare system, enabling a shift from expensive operating rooms to cost-effective office-based surgery, while offering patients scar-free healing and immediate return to daily activities. The first applications are carpal tunnel and trigger finger surgery, affecting one person on seven. Spirecut patented instruments are CE-marked and the company is FDA-listed. Spirecut successfully launched market in 2024, selling more than 6’000 kits for over CHF 1Mn in revenue. Spirecut has eight publications in peer-reviewed medical journals. Spirecut, with subsidiaries in Belgium, USA and Hong Kong, has raised CHF 2.5M from private investors. The current round (series A) of CHF 10 Mn (equity) is needed for scale and R/D, as Spirecut ambitions to become the global leader of ultra- minimally invasive surgery (sonography-guided, incisionless). Exit in 2031 as IPO.

Marine Biomedical is developing PearlBone™, a nacre-derived bone graft substitute for the repair of bony voids and defects in orthopaedic and trauma applications. PearlBone™ is manufactured from pearl shell-derived biomaterials and is designed to support bone regeneration using a bioinspired mineral scaffold.

Maxonis is developing a novel peptide therapeutic targeting nerve regeneration via local surgical delivery. Primary target is Peripheral Nerve Injury (PNI), specifically to restore patients' sensory and motor function.

Noleus Technologies is a clinical-stage company developing a proprietary platform to reduce length of stay (LOS) and reduce complications for abdominal surgery patients. Its first product treats post-op ileus (POI), the most common cause of complications and extended stay after abdominal surgery. This is a $30B problem with nearly 3M US patients suffering from ileus annually, and a TAM is $8B and Noleus can save an average high-volume hospital $50M per year.

Vigocare is a cardiac rhythm intelligence platform that turns continuous ECG data from any clinical-grade wearable into AI-driven diagnosis, decision support, and reimbursable care. Its AI extracts a far wider set of features from the ECG than traditional methods, enabling cardiac screening at scale across India and Australia. The platform is device-agnostic by design, so its value compounds with every new sensor that comes to market.

ArthroLase is an Australian medical device company developing an intelligent robotic laser bone shaping system for knee replacement and resurfacing surgery. Its two core platforms, HAiLO and AIRO-x, integrate non-contact high-speed laser bone cutting with surgical robotics, real-time intraoperative 3D digital sensing, and intelligent computer control to achieve sub-millimetre precision in osteotomy procedures. 

Materia Health is an early-stage medical technology company offering the MateriaPOD, a smart, portable preservation platform designed to replace legacy ice-based storage for donor organs, tissues, and blood products. The technology utilizes active, software-driven temperature control and internal pressure cushioning to maximize cellular viability and reduce transplant complications. Differentiated by its robust, multi-application architecture, Materia Health is optimizing its reusable capsule to solve critical biological logistics challenges in human healthcare, defense trauma care, and veterinary science.

Ferronova's lead product, FerroTrace, is a magnetic nanoparticle tracer injected around a primary tumour prior to surgery. The nanoparticles follow the body's natural lymphatic pathways — the same routes through which cancer spreads — allowing surgeons to intraoperatively identify high risk lymph nodes with accompanying surgical devices. The novel FerroTrace formulation is designed to be retained in lymph nodes for >6 months, overcoming the major problem with other "tracers" which are ineffective after pre-surgical neoadjuvant treatment.

Monitra Health builds upBeat®, a remote cardiac monitoring platform for both short- and long-term studies, improving diagnostic yield. Used across 50,000+ patients in India, it has assembled a proprietary dataset of 10B+ labeled heartbeats and three granted patents — the foundation for a planned cardiac AI engine. FDA 510(k) and EU MDR pathways underway.

The Kiffik wearable device will give easy access to 12,500 clinically important biomarkers. This non-invasive (no nurse no needle) wearable enables more companion diagnostics & point of care testing to move away from the hindrance of needing a blood sample. Interstitial fluid will become the Biofluid of Choice for many existing tests and reduce dependence upon laboratory testing in Biochemistry, Immunology & Serology. It may also enhance genetics/oncology testing with biomarkers showing up in ISF before they are detectable in plasma.We seek partners to explore moving existing lab-based testing into point of care settings. This will give first mover advantage to many companies seeking to gain competitive USPs for existing product lines.